Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam

Pharmacotherapy

Volumn 34, Issue 7, 2014, Pages 670-676

  Burgess, Lindsey D ^a   Drew, Richard H ^a,b  

^a DUKE UNIVERSITY HOSPITAL   (United States)

^b CAMPBELL UNIVERSITY   (United States)

Author keywords

acute kidney injury; nephrotoxicity; piperacillin tazobactam; vancomycin

Indexed keywords

CREATININE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ABDOMINAL INFECTION; ADULT; AGE; ARTICLE; BLOODSTREAM INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HOSPITAL PATIENT; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SKIN INFECTION; STEADY STATE; TERTIARY CARE CENTER; URINARY TRACT INFECTION; VANCOMYCIN INDUCED NEPHROTOXICITY; ACUTE KIDNEY INJURY; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED; TRENDS;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84903851914     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1442     Document Type: Article

References (17)

1. Elyasi S, Khalili H, Dashti-Khavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68: 1243-55.
2. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-8.
3. Pannu N, Nadim M,. An overview of drug-induced acute kidney injury. Crit Care Med 2008; 36 (Suppl. 4): 216-23.
4. Levine D,. Vancomycin: a history. Clin Infect Dis 2006; 42: S5-12.
5. van Hal SJ, Paterson DL, Lodise TP,. Systemic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57: 734-44.
6. Lodise TP, Lomaestro B, Graves J, Drusano GL,. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6.
7. Jensen J-US, Hein L, Lundgren B, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open 2012; 2: 1-8.
8. Pfizer. Zosyn (piperacillin-tazobactam) package insert. Philadelphia, PA: Pfizer; 2012.
9. Min E, Box K, Lane J, et al. Acute kidney injury in patients receiving concomitant vancomycin and piperacillin-tazobactam (Abstract). Crit Care Med 2011; 39 (Suppl. 12): 200.
10. Hellwig T, Hammerquist R, Loecker JS, et al. Retrospective evaluation of the incidence of vancomycin and/or piperacillin-tazobactam induced acute renal failure (Abstract). Crit Care Med 2011; 39 (Suppl. 12): 79.
11. Farber BF, Moellering RC,. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138-41.
12. Bauer LE,. Applied clinical pharmacokinetics. New York: McGraw-Hill; 2008.
13. Bellomo R, Ronco C, Kellum J, et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-12.
14. Pakyz AL, MacDougall C, Oinonen M, Polk RE,. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 2008; 168: 2254-60.
15. Gupta A, Biyani M, Khaira A,. Vancomycin nephrotoxicity: myths and facts. Neth J Med 2011; 69: 379-83.
16. Moellering RC,. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006; 42 (Suppl. 1): s3-4.
17. Jeffres MN, Isakow W, Joshua AD, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107-15.